Loading stock data…
Simulations Plus (SLP)
$18.38+0.18 (+0.99%)
Market ClosedLast close Jun 29
Simulations Plus, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Simulations Plus, Inc. in the Healthcare sector is trading at $18.38 with a market capitalization of $369M. Wall Street consensus targets $17.25 (2 analysts), implying a -6.1% move over the next 12 months. The stock is currently 13% below its 52-week high of $21.01, remaining 16.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -6.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.29M↑ | $18.42M↑ | $17.46M↓ | $20.36M↓ | $22.43M |
| Gross Profit | $16.14M↑ | $10.89M↑ | $9.84M↓ | $13.03M↓ | $13.13M |
| Operating Income | $5.63M↑ | $713,000↑ | $659,000↓ | $3.00M↑ | $2.71M |
| Net Income | $4.54M↑ | $676,000↑ | -$681,000↑ | -$67.32M↓ | $3.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Softwar...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$369.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-46.94%
Volume
Today's trading volume
560,881
Recent News
Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets
Certara’s updated analyst model now carries a slightly lower fair value price target of US$7.48, compared with the prior US$7.62, reflecting only a modest adjustment. This small move aligns with recent Street commentary, where bullish analysts highlight profitable operations and long term growth drivers, while more cautious voices trim targets as they reassess valuation multiples and execution timelines. As you read on, you will see how these shifting views fit together and how to keep track...
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
Altaris to acquire Simulations Plus in $375m all-cash deal
Completion of the transaction is expected in the fourth quarter of 2026.
Sector Update: Tech Stocks Fall Tuesday Afternoon
Tech stocks were lower Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (X
Why Shares in Simulation Plus Soared Today
Shareholders woke up to the idea that their company will have a new owner by the end of the year.